Collectively, these data establish that pharmacological modulation of the PAR-2/ERK/TNF-α axis by statins redirects inflammatory colorectal cancer cells from survival toward programmed cell death, with rosuvastatin demonstrating consistently greater potency than atorvastatin. The gene discussed is MAPK1; the disease is colorectal cancer.